Adam C Palmer
@ac_palmer
Followers
807
Following
2K
Media
91
Statuses
766
Assistant Professor, Pharmacology and Computational Medicine at @UNC Measuring and modeling combination cancer therapy
Chapel Hill, NC
Joined May 2012
New paper by @AmyEPomeroy! A model of intratumor and interpatient heterogeneity explains clinical trials of curative combination therapy for lymphoma Out now in Blood Cancer Discovery @BCD_AACR
https://t.co/NTWoC8qns3
#mathonc #lymsm #BloodCancer 1/n
7
8
32
Cell-Of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B Cell Lymphoma
aacrjournals.org
Abstract. Purpose: Polatuzumab vedotin (polatuzumab) was approved for upfront treatment of diffuse large B-cell lymphoma (DLBCL) in combination with chemoimmunotherapy (Pola-R-CHP) based on the...
0
15
50
🚨Just out @CCR_AACR 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks @dgermain21 & collabs! https://t.co/kGyRneMAuo
7
28
88
This would be an amazing position for a postdoc interested in tumor evolution
We are hiring a postdoc to profile the evolvability of tumors in longitudinal samples from three clinical trials as part of the ARPA-H ADAPT program. This is essentially an evolutionary bioinformatics position. If you are interested, please apply here ASAP
0
1
0
A fascinating read regarding 'ambition versus precision' in clinical trial design - relevant to all areas of oncology.
Just out in @JCO_ASCO, @MyMKaiser and I reflect on the tumultuous development of venetoclax for t(11;14) myeloma, examining the challenges, lessons for drug development and future directions for BCL2i in myeloma https://t.co/XlBf4qwCPS
#mmsm
1
2
4
Cancer is an evolutionary disease, but does knowing a cancer’s evolutionary past help predict its future? Out today in @Nature, we learnt the evolution of 2000 lymphoid cancers and found it was highly correlated with clinical outcomes! (1/7, link below)
11
122
601
In the United States, the overall cancer death rate has been steadily declining since the 1990s, with the reductions between 1991 and 2021 translating into more than 4.1 million cancer deaths avoided. https://t.co/19HczuNCFa
1
2
7
Our new editorial just published in @BMJOncology led by @lateuwen where we discuss the use of inferior control arm in cancer drug trials run in LMICs. https://t.co/m1fwEkZu6N
3
17
58
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma. Co-authored by @AshAlizadeh, @RoschewskiMD, @DrJasonWestin, @max_diehn, @Rcl14L Read the full article. https://t.co/GvDwbaivb4
#lymsm
ascopubs.org
PURPOSELarge B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA)...
0
13
43
Here are some rambling thoughts of mine on this topic. I'm critical of studies that open with a control arm known to be inferior (for the primary endpoint) compared to an alternative regimen. Just because the trial was conceived and protocol written years before activation, we
@Ivaj960612 @GuiperiniMD @JacobPlieth I think the 'quality of control arm' controversies and debates that've been brewing over the past few years are really still in the early phases and we have a long way to go to modernize how we think about choice of control arms, what to do mid-trial if 'better' options emerge,
1
3
12
Abstract submission is now open for #MathOnco25! So please go ahead and submit asap to have a chance of getting one of our travel awards:
0
3
5
Save-the-date: AACR/ICML Advances In Malignant Lymphoma, June 24-27, 2026, Philadelphia. Featuring interactive sessions focused on the cutting edge of basic and translational research in Lymphoma. @AACR @icmlugano #lmsm
0
3
27
What I have been worried about. We now spend more on health care than groceries or housing. And it’s not going to slow down. See Thread. https://t.co/dqk6pOfahZ
4
7
23
Atul Butte in memoriam https://t.co/M6wlgslg4N
@UCSF @StanfordMed @Harvard @BostonChildrens @BrownUniversity
ucsf.edu
Atul Butte, who championed the use of big data in science and health care and inspired a generation of trainees at UC San Francisco and beyond to pursue the fields he pioneered — translational and...
0
23
89
The big debate 3: Smith vs Nowakowski: Is Pola-R-CHP the new standard for all DLBCL? No.
1
5
35
Pola-R-CHP the new SOC for ALL DLBCL? @SoniSmithMD YES vs. @GregNowakowski NO Pola-R-CHP, RCHOP Some need Pola-R-CHP Some don't have access to Pola Some will be fine with RCHOP @icmlugano #18ICML #lymsm
5
3
9
Two great resources on the latest in lymphoma: 1) MD Academy has free recordings of 2025 CLL+Lymphoma meeting https://t.co/dMiHrI7deb 2) Blood Cancer Discovery has a free collection of lymphoma articles, including a review on ctDNA applications https://t.co/1x729wdEY5
#lymsm
academy.md-education.com
We are excited to share the video course from the 4th Annual CLL-Lymphoma US Focus Meeting 2025, held at the Marina del Rey Marriott Hotel, Santa Monica, CA, on May 2-3, 2025
4
0
2
This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
54
491
1K
Clear and compelling interview with @baym on the harm of cutting funding to antibiotic research: https://t.co/KehKBrDl51 This affects so much of modern medicine; many cancer treatments, including regimens with curative intent, are only safe because of effective antibiotics.
wbur.org
Microbiologist Michael Baym studies antibiotic resistance at Harvard Medical School. He lost millions in federal funding this week.
0
15
24
Yesterday, the NIH R35 “Outstanding Investigator” grant to fund scientists in my lab studying antibiotic resistance was terminated for reasons not related to the content of the science, or any actions taken by me or members of my lab
79
220
851
Thank you @ac_palmer for speaking in the MCMC seminar! The seminar recording is available here:
Excited to announce the second Mathematical and Computational Modeling of Cancer (MCMC) Seminar speaker, Adam Palmer from University of North Carolina, who will be talking on "Modeling tumor heterogeneity to understand the clinical efficacy of combination therapy". 1/3
0
3
9